If you have been reading about research peptide and want a single page that covers the useful parts, this is it: definitions, context, how it is studied, and the questions that come up repeatedly.
Updated 2026-08-01. Numbers and descriptions here follow the published literature rather than marketing material.
Discussion of TB-500 appears in several distinct literatures that rarely cite one another. Peer-reviewed studies usually describe in vitro assays or small animal experiments and are cautious about extrapolation. Veterinary and sports communities circulate anecdotal reports with limited methodological detail. Commercial listings add a third layer, often using the name interchangeably with thymosin beta-4 even though the two molecules differ in size and sequence. Regulatory status varies by country, and the compound is not a licensed medicine in most jurisdictions, so readers comparing sources should check which molecule and which purity each source actually describes.
TB-500 is a synthetic seven-residue peptide whose sequence, LKKTETQ, matches the N-terminal actin-binding region of thymosin beta-4. It is usually supplied in an N-terminally acetylated form, a modification that blocks the free amino terminus and can influence behavior in solution. In the research literature the same sequence appears under several names, including thymosin beta-4 fragment and shortened thymosin beta-4. Because it is a short peptide rather than the full 43-residue parent protein, its measured properties differ from those reported for thymosin beta-4 as a whole, and the two are not interchangeable in experimental design.
Thymosin beta-4 itself is a small, widely expressed protein that sequesters monomeric actin and participates in cell migration, angiogenesis, and tissue repair. Researchers have examined the shortened fragment as a possible mimic of some of these activities, reasoning that the actin-binding motif lies within the first few residues. Binding to monomeric actin has been observed in cell-free systems. Whether the fragment reproduces the broader effects of the full protein in living tissue remains an open question, and findings from animal models are frequently cited without a clear bridge to human physiology.
Material sold under this label typically arrives as a freeze-dried powder in a sealed vial with a certificate of analysis. Such certificates usually report reversed-phase chromatography purity plus a mass confirmation, and stated purities commonly sit between 95 and 99 percent. Counter-ion identity, residual trifluoroacetate, water content, and peptide net weight are separate specifications that a certificate may or may not include. A purity figure alone does not establish sequence identity, so independent mass verification remains the practical check.
The designation TB-500 circulates in laboratory and catalog contexts without a single agreed definition. Most product listings apply it to an N-terminally acetylated seven-residue fragment of thymosin beta-4, while other listings attach the same label to the full 43-residue protein. Because the term is commercial rather than systematic, two entries bearing identical names may describe different molecules. Any documentation should therefore state which sequence a given sample is claimed to contain.
The fragment most often associated with the name carries the sequence Ac-LKKTETQ, matching residues 17 through 23 of thymosin beta-4. That region holds the actin-binding motif responsible for much of the parent protein's biochemical activity. Apart from N-terminal acetylation the peptide is unmodified and contains no disulfide bonds, so it shows little ordered secondary structure in solution. Full-length thymosin beta-4 is instead a 43-residue polypeptide of roughly 4.9 kDa found widely across mammalian cell types.
| Property | Value | Notes |
|---|---|---|
| Molecular class | Synthetic peptide | N-terminal fragment of thymosin beta-4 |
| Residue count | Seven | Sequence LKKTETQ |
| Approximate mass | 889 Da | Acetylated seven-residue peptide |
| Common synonyms | TB4 fragment, TB500 | Not identical to full-length TB4 |
| Reported activity | Actin binding | Observed mainly in cell-free systems |
The compound circulates in the literature as a research reagent rather than an approved therapeutic. Regulatory agencies in several countries have not authorized it for medical use, and sporting bodies list related thymosin beta-4 peptides among prohibited substances. Suppliers typically market it with a purity figure and a certificate of analysis, while peer-reviewed clinical reports remain sparse. Discussions therefore often separate laboratory findings from anecdotal reports, and reviewers tend to note the small size and methodological limits of the available studies.
TB-500 refers to a synthetic peptide fragment derived from the actin-binding region of thymosin beta-4, a protein present in most mammalian cells. The full protein contains forty-three amino acids, while the commonly sold fragment is a much shorter acetylated sequence, often cited as LKKTETQ. The fragment retains part of the actin-binding motif but lacks the remainder of the parent protein. Material sold under this name is usually lyophilized powder intended for laboratory research, and it is not a finished pharmaceutical product.
Proposed activity centers on actin sequestration and on the movement of cells during repair processes. In cell culture and animal models, the fragment has been associated with migration, tube formation, and tissue remodeling. These observations are frequently described as preliminary, because most published work uses rodent or in vitro systems rather than controlled human trials. Whether the short fragment reproduces the effects of the full protein remains an open question, and the relationship between dose, route, and measured outcome is not well characterized.
Published work involving this sequence spans actin-binding assays, cell-migration studies, wound-healing models, and cardiovascular or musculoskeletal experiments. Much of the biological rationale derives from in vitro systems and animal models, and the number of controlled human studies is small. Reported outcomes vary across preparations, doses, and routes, which complicates comparison between studies. Reviews generally describe the evidence base as preliminary rather than settled. Mechanistic explanations are often proposed by analogy to the parent protein rather than demonstrated directly.
TB-500 is a synthetic seven-amino-acid peptide with the sequence LKKTETQ, corresponding to residues 17 through 23 of the protein thymosin beta-4. The N-terminus is typically acetylated in the described form, giving a monoisotopic mass near 888.5 Da and an average mass of about 889 Da. The designation TB-500 is a catalogue label rather than a formal chemical name, and the same sequence appears in the literature under several alternative abbreviations. It is handled as a research reagent rather than a pharmaceutical product.
Thymosin beta-4 is a 43-residue actin-binding protein found in most mammalian cell types, where it participates in cytoskeletal regulation and cell migration. TB-500 represents only a short fragment of that protein and does not include the remaining residues. Whether the isolated fragment reproduces the full range of activities reported for the intact protein remains an open question. Researchers commonly treat the two as related but distinct entities when comparing results.
Several names appear in scientific and commercial contexts for this peptide. The label TB-500 is informal and does not follow standard biochemical nomenclature. Research articles more often describe the compound as a thymosin beta-4 fragment, Tβ4 fragment, or by its sequence Ac-LKKTETQ. Confusing TB-500 with full-length thymosin beta-4 can lead to incorrect assumptions about activity because the fragment lacks the remaining residues of the parent protein. The relationship between fragment and parent protein remains an active area of study.
Regulatory status differs by country, but TB-500 is not an approved pharmaceutical in major jurisdictions. It is commonly sold as a research chemical for laboratory use, which places responsibility for identity and purity on the supplier and the laboratory. Published human data are limited, and most reports involve preclinical models or cell culture. Questions about whether the fragment mimics all actions of thymosin beta-4, and under which conditions, remain open. Independent verification of any material is therefore a practical requirement in research settings.
TB-500 is a synthetic heptapeptide with the sequence Ac-LKKTETQ. It corresponds to a short N-terminal region of thymosin beta-4, a 43-amino-acid protein found in many cell types. The fragment contains an actin-binding motif, which is one reason it appears in laboratory studies of cell migration and cytoskeletal dynamics. TB-500 is not the full-length protein and is produced as a research chemical rather than an approved therapeutic agent. Its molecular weight is approximately 889 Da.
TB-500 is a short synthetic peptide sold under a trade name rather than a systematic chemical name. Suppliers usually describe it as a fragment of thymosin beta-4 and ship it as a lyophilised powder intended for laboratory use. Because the label is commercial, the exact sequence attributed to it is not fully consistent across catalogues, and some listings present a seven-residue peptide while others describe related fragments of similar length. It is not an approved medicine in any major jurisdiction, and it is handled as a research chemical.
Thymosin beta-4 itself is a natural peptide of 43 residues found in many cell types and body fluids. Its best-characterised function is binding and sequestering actin monomers, which influences cytoskeletal dynamics. The sequence most often associated with TB-500, LKKTETQ, corresponds to part of that actin-binding region. A different fragment, Ac-SDKP, is also derived from the same parent peptide and is studied in its own right, which is one reason discussions of thymosin fragments can become confusing. The two are structurally distinct and are not interchangeable.
In invertebrates, a body fluid analogous to blood called hemolymph is found, the main difference being that hemolymph is not contained in a closed circulatory system. Hemolymph may function to carry oxygen, although hemoglobin is not necessarily used. Crustaceans and mollusks use hemocyanin instead of hemoglobin. In most insects, their hemolymph does not contain oxygen-carrying molecules because their bodies are small enough for their tracheal system to suffice for supplying oxygen.
Actin filaments, the thin filaments, are the major component of the I-band and extend into the A-band. Myosin filaments, the thick filaments, are bipolar and extend throughout the A-band. They are cross-linked at the centre by the M-band. The giant protein titin (connectin) extends from the Z-line of the sarcomere, where it binds to the thick filament (myosin) system, to the M-band, where it is thought to interact with the thick filaments. Titin (and its splice isoforms) is the biggest single highly elasticated protein found in nature. It provides binding sites for numerous proteins and is thought to play an important role as sarcomeric ruler and as blueprint for the assembly of the sarcomere. Another giant protein, nebulin, is hypothesised to extend along the thin filaments and the entire I-Band. Similar to titin, it is thought to act as a molecular ruler along for thin filament assembly. Several proteins important for the stability of the sarcomeric structure are found in the Z-line as well as in the M-band of the sarcomere. Actin filaments and titin molecules are cross-linked in the Z-disc via the Z-line protein alpha-actinin. The M-band proteins myomesin as well as C-protein crosslink the thick filament system (myosins) and the M-band part of titin (the elastic filaments). The M-line also binds creatine kinase, which facilitates the reaction of ADP and phosphocreatine into ATP and creatine. The interaction between actin and myosin filaments in the A-band of the sarcomere is responsible for the muscle contraction (based on the sliding filament model).
The cement production process is responsible for nearly 8% (2018) of global CO2 emissions, which includes heating raw materials in a cement kiln by fuel combustion and release of CO2 stored in the calcium carbonate (the calcination process). Its hydrated products, such as concrete, gradually reabsorb atmospheric CO2 (carbonation process), compensating for approximately 30% of the initial CO2 emissions. silicon dioxide
=== Positive symptoms === Positive symptoms are those for which function is gained: paresthesias, increased sensitivity, pain, muscle spasms, fasciculations. The symptoms represent hyperexcitability of a nerve where a signal is sent along a nerve due to a lower threshold for activation resulting in spontaneous signals. Demyelination can cause positive sensory symptoms such as pain due to increased ectopic firing. Demyelinated nerve tissue has been found to have a lower activation threshold for sending a signal, specifically for mechanosensitivity (e.g. light touch). While is some debate about the role of central nervous system sensitization in painful entrapment neuropathies, the success of peripheral nerve blocks suggests a peripheral nerve origin of this neuropathic pain.
=== Psychotic symptoms === BPD is predominantly characterized as a disorder involving emotional dysregulation, yet psychotic symptoms frequently occur in individuals with BPD, with about 20–50% of patients reporting psychotic symptoms. These manifestations have historically been labeled as "pseudo-psychotic" or "psychotic-like", implying a differentiation from symptoms observed in primary psychotic disorders. Studies conducted in the 2010s suggest a closer similarity between psychotic symptoms in BPD and those in recognized psychotic disorders than previously understood. The distinction of pseudo-psychosis has faced criticism for its weak construct validity and the potential to diminish the perceived severity of these symptoms, potentially hindering accurate diagnosis and effective treatment. Consequently, there are suggestions from some in the research community to categorize these symptoms as genuine psychosis, advocating for the abolition of the distinction between pseudo-psychosis and true psychosis. The DSM-5 identifies transient paranoia, exacerbated by stress, as a symptom of BPD. Research has identified the presence of both hallucinations and delusions in individuals with BPD who do not possess an alternate diagnosis that would better explain these symptoms. Further, phenomenological analysis indicates that auditory verbal hallucinations in BPD patients are indistinguishable from those observed in schizophrenia.
Sources: en.wikipedia.org
Production of instant tea can be broken down into six main steps: selection of raw materials, extraction, aroma stripping, tea cream processing, concentration, and drying. Selection of tea leaves is done with the best interests of both the manufacturer and end user. Because of certain legal restrictions in tea producing countries, it is most cost effective for manufacturers to use fermented, undried black leaves, as they do not have to pass through public auctions and are therefore cheaper. Quality is not sacrificed, as research has been done to show that this type of leaf has similar flavor when compared to dried, black leaves. Extraction is done with two goals in mind: yield of tea solids extracted from the leaf, and concentration of the extract solution. Research has shown that tea leaf solubles in a column extractor can be described in a system of three components, each which obey a first-order solution law. The explanation given for why the soluble compounds fall into any of these three categories is based on how accessible they are. The instantly soluble compounds are likely to be right on the surface of the leaf, which is why they are the first to be obtained. The rapidly soluble components are thought to be from the inside of the leaves, where broken cell structures slow both the rate of solvent entering as well as solute leaving. The slowest soluble compounds are expected to have either high molecular mass, which would take longer to move through the cell matrices of the leaves, or products formed during hydrolysis over the course of the extraction.
These methods have since been adopted as a clinical standard for accelerated MRI at several major medical centers. The record for the highest spatial resolution of a whole intact brain (postmortem) is 100 microns, from Massachusetts General Hospital. The data was published in Nature in October 2019. Though MRI is used widely in research on mental disabilities, based on a 2024 systematic literature review and meta analysis commissioned by the Patient-Centered Outcomes Research Institute (PCORI), available research using MRI scans to diagnose ADHD showed great variability. The authors conclude that MRI cannot be reliably used to assist in making a clinical diagnosis of ADHD.
A PLC assembly consists of seven subunits, including the transporters associated with antigen processing (TAP1 and TAP2 – jointly referred to as TAP), the oxidoreductase ERp57, the MHC-I heterodimer, and the chaperones tapasin and calreticulin. TAP transports proteasomal degradation products from the cytosol into the lumen of the ER, where they are loaded onto MHC-I molecules. The peptide-MHC-I complexes then move via a secretory pathway to the cell surface, presenting their antigenic load to cytotoxic T-cells. In general, preliminary MHC-I heavy chains are chaperoned by the calnexin–calreticulin system in the ER. Together with β2-microglobulin (β2m), MHC-I heavy chains form assemblies of heterodimers that act as receptors for antigenic peptides. Empty MHC-I heterodimers are recruited by calreticulin and form short-lived macromolecular PLC where the chaperone tapasin further provides stabilization in the MHC-I molecules. Furthermore, ERp57 and tapasin form disulfide-linked conjugates, and tapasin is crucial for maintaining the structural stability of the PLC as well as facilitating optimal peptide loading. After final quality control, during which MHC-I heterodimers undergo peptide editing, stable peptide–MHC-I complexes are released to the cell surface for T-cell recognition. The PLC can serve a large variety of MHC-I allomorphs, thus playing a central role in the differentiation and priming of T lymphocytes, and in controlling viral infections and tumour development.
Aberrant basal cell carcinoma Acanthoma fissuratum (granuloma fissuratum, spectacle frame acanthoma) Acrospiroma (clear cell hidradenoma, dermal duct tumor, hidroacanthoma simplex, nodular hidradenoma, poroma) Actinic keratosis (senile keratosis, solar keratosis) Adenoid squamous cell carcinoma (pseudoglandular squamous cell carcinoma) Aggressive digital papillary adenocarcinoma (digital papillary adenocarcinoma, papillary adenoma) Apocrine gland carcinoma Apocrine nevus Arsenical keratosis Atrophic actinic keratosis Balanitis plasmacellularis (balanoposthitis chronica circumscripta plasmacellularis, balanitis circumscripta plasmacellularis, plasma cell balanitis, plasma cell vulvitis, vulvitis circumscripta plasmacellularis, Zoon's balanitis, Zoon's erythroplasia, Zoon's vulvitis) Basal cell carcinoma Basaloid follicular hamartoma Basaloid squamous cell carcinoma Birt–Hogg–Dubé syndrome Bowen's disease (squamous cell carcinoma in situ) Brooke–Fordyce syndrome Ceruminoma Cicatricial basal cell carcinoma (morpheaform basal cell carcinoma, morphoeic basal cell carcinoma) Ciliated cyst of the vulva (cutaneous Müllerian cyst, paramesonephric mucinous cyst of the vulva) Clear cell acanthoma (acanthome cellules claires of Degos and Civatte, Degos acanthoma, pale cell acanthoma) Clear cell squamous cell carcinoma (clear cell carcinoma of the skin) Chronic scar keratosis (chronic cicatrix keratosis) Clonal seborrheic keratosis Common seborrheic keratosis (basal cell papilloma, solid seborrheic keratosis) Cowden syndrome (Cowden's disease, multiple hamartoma syndrome) Cutaneous ciliated cyst Cutaneous columnar cyst Cutaneous horn (Cornu cutaneum) Cystic basal cell carcinoma Dermal eccrine cylindroma (cylindroma) Dermatosis papulosa nigra Desmoplastic trichoepithelioma Dilated pore (dilated pore of Winer) Eccrine carcinoma (syringoid carcinoma) Eccrine nevus Epidermal cyst (epidermal inclusion cyst, epidermoid cyst, infundibular cyst, keratin cyst) Epidermal nevus syndrome (Feuerstein and Mims syndrome, Solomon's syndrome) Epidermolytic acanthoma Epithelioma cuniculatum (Ackerman tumor, carcinoma cuniculatum) Eruptive vellus hair cyst Erythroplasia of Queyrat Extramammary Paget's disease Fibroepithelioma Fibroepithelioma of Pinkus Fibrofolliculoma Follicular hybrid cyst (Hybrid cyst) Folliculosebaceous-apocrine hamartoma (follicular-apocrine hamartoma) Folliculosebaceous cystic hamartoma Generalized eruptive keratoacanthoma (generalized eruptive keratoacanthoma of Grzybowski) Giant solitary trichoepithelioma Hidradenoma Hidradenocarcinoma Hidrocystoma (cystadenoma, Moll's gland cyst, sudoriferous cyst) Hydrocarbon keratosis (pitch keratosis, tar keratosis, tar wart) Hyperkeratosis lenticularis perstans (Flegel's disease) Hyperkeratosis of the nipple and areola Hyperkeratotic actinic keratosis Ichthyosis hystrix (ichthyosis hystrix gravior type Lambert, porcupine man, systematized verrucous nevus) Ichthyosis hystrix of Curth–Macklin Infiltrative basal cell carcinoma Inflammatory linear verrucous epidermal nevus Inverted follicular keratosis Irritated seborrheic keratosis (basosquamous cell acanthoma, inflamed seborrheic keratosis) Isthmicoma (infundibuloma, tumor of the follicular infundibulum) Juvenile myelomonocytic leukemia Keratin implantation cyst Keratoacanthoma Keratoacanthoma centrifugum marginatum Large cell acanthoma Lichenoid actinic keratosis Lichenoid keratosis (benign lichenoid keratosis, lichen planus-like keratosis, solitary lichen planus, solitary lichenoid keratosis) Linear verrucous epidermal nevus (linear epidermal nevus, verrucous epidermal nevus) Malignant acrospiroma (spiradenocarcinoma) Malignant mixed tumor (malignant chondroid syringoma) Malignant trichilemmal cyst Mantleoma Marjolin's ulcer Melanoacanthoma (pigmented seborrheic keratosis) Merkel cell carcinoma (cutaneous apudoma, primary neuroendocrine carcinoma of the skin, primary small cell carcinoma of the skin, trabecular carcinoma of the skin) Microcystic adnexal carcinoma (sclerosing sweat duct carcinoma) Micronodular basal cell carcinoma Milia en plaque Milium Mixed tumor (chondroid syringoma) Mucinous carcinoma Mucinous nevus (nevus mucinosus) Muir–Torre syndrome Multiple familial trichoepithelioma (Brooke–Spiegler syndrome, epithelioma adenoides cysticum) Multiple keratoacanthomas (Ferguson–Smith syndrome, Ferguson-Smith type of multiple self-healing keratoacanthomas, multiple keratoacanthomas of the Ferguson–Smith type) Multiple minute digitate hyperkeratosis (digitate keratoses, disseminated spiked hyperkeratosis, familial disseminated piliform hyperkeratosis, minute aggregate keratosis) Nevoid basal cell carcinoma syndrome (basal cell nevus syndrome, Gorlin syndrome, Gorlin–Goltz syndrome) Nevus comedonicus (comedo nevus) Nevus comedonicus syndrome Nevus sebaceous (nevus sebaceous of Jadassohn, organoid nevus) Nevus unius lateris Nodular basal cell carcinoma (classic basal cell carcinoma) Paget's disease of the breast Papillary eccrine adenoma (tubular apocrine adenoma) Papillary hidradenoma (hidradenoma papilliferum) Papillomatosis cutis carcinoides (Gottron's carcinoid papillomatosis, papillomatosis cutis carcinoides of Gottron–Eisenlohr) Patch blue nevus (acquired dermal melanocytosis, dermal melanocyte hamartoma) Perifollicular fibroma Phakomatosis pigmentokeratotica Pigmented actinic keratosis Pigmented basal cell carcinoma Pigmented hairy epidermal nevus syndrome Pilar sheath acanthoma Pilonidal sinus (Barber's interdigital pilonidal sinus, pilonidal cyst, pilonidal disease) Porocarcinoma (malignant poroma, eccrine porocarcinoma) Polypoid basal cell carcinoma Pore-like basal cell carcinoma Primary cutaneous adenoid cystic carcinoma Proliferating epidermoid cyst (proliferating epithelial cyst) Proliferating trichilemmal cyst (pilar tumor, proliferating follicular cystic neoplasm, proliferating pilar tumor, proliferating trichilemmal tumor) Pseudocyst of the auricle (auricular endochondrial pseudocyst, cystic chondromalacia, endochondral pseudocyst, intracartilaginous cyst) Pseudoepitheliomatous keratotic and micaceous balanitis PUVA keratosis Rasmussen syndrome Reactional keratosis Reticulated seborrheic keratosis (adenoid seborrheic keratosis) Rodent ulcer (Jacobi ulcer) Schimmelpenning syndrome (Schimmelpenning–Feuerstein–Mims syndrome) Sebaceoma (sebaceous epithelioma) Sebaceous adenoma Sebaceous carcinoma Sebaceous hyperplasia Sebaceous nevus syndrome Seboacanthoma Seborrheic keratosis (seborrheic verruca, senile wart) Seborrheic keratosis with squamous atypia Signet-ring cell squamous cell carcinoma Solitary keratoacanthoma (subungual keratoacanthoma) Solitary trichoepithelioma Spindle cell squamous cell carcinoma (spindle cell carcinoma) Spiradenoma Squamous cell carcinoma Steatocystoma multiplex (epidermal polycystic disease, sebocystomatosis) Steatocystoma simplex (simple sebaceous duct cyst, solitary steatocystoma) Stucco keratosis (digitate seborrheic keratosis, hyperkeratotic seborrheic keratosis, keratosis alba, serrated seborrheic keratosis, verrucous seborrheic keratosis) Superficial basal cell carcinoma (superficial multicentric basal cell carcinoma) Syringadenoma papilliferum (syringocystadenoma papilliferum) Syringofibroadenoma (acrosyringeal nevus of Weedon and Lewis) Syringoma Systematized epidermal nevus Thermal keratosis Trichilemmal carcinoma Trichilemmal cyst (isthmus-catagen cyst, pilar cyst) Trichilemmoma Trichoadenoma (trichoadenoma of Nikolowski) Trichoblastoma Trichoblastic fibroma Trichodiscoma Trichofolliculoma Unilateral palmoplantar verrucous nevus Urethral caruncle Verrucous carcinoma Verrucous cyst (cystic papilloma) Viral keratosis Warty dyskeratoma (isolated dyskeratosis follicularis) Waxy keratosis of childhood (kerinokeratosis papulosa) Zoon's vulvitis Zosteriform speckled lentiginous nevus
==== Short-term ==== Acute adverse effects are usually the result of high or multiple doses, although single dose toxicity can occur in susceptible individuals. The most serious short-term physical health risks of MDMA are hyperthermia and dehydration. Cases of life-threatening or fatal hyponatremia (excessively low sodium concentration in the blood) have developed in MDMA users attempting to prevent dehydration by consuming excessive amounts of water without replenishing electrolytes. The immediate adverse effects of MDMA use can include:
Sources: en.wikipedia.org
No. Thymosin beta-4 is a 43-residue protein, while TB-500 refers to a seven-residue fragment corresponding to its N-terminal region. The two names are often used loosely in commercial and community writing, which obscures the difference in size, sequence, and likely behavior.
The fragment contains an actin-binding motif, and cell-free experiments show that it can interact with monomeric actin. That observation is the basis for interest in cell migration and repair processes. Effects reported in animals are not established for humans.
Purity is usually stated by the supplier rather than fixed by a pharmacopoeial monograph, and typical listings report a percentage from reverse-phase HPLC. Independent verification is uncommon. Because no single accepted specification exists, comparisons between lots and between suppliers are difficult.
Usually not, though usage overlaps. The label most often refers to a short acetylated fragment of the parent protein, while thymosin beta-4 itself is the full 43-residue molecule. Because suppliers vary, a sequence statement is needed to settle the question for any particular lot.